Category: Disease progression

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU (European Union) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

Paris, June 23, 2026. The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS)…

Stuart Schlossman

Understanding Disability Progression in MS

Please register for this event by clicking the orange “Register for Virtual Event” button, below Topic Discussions: Guest Speaker: Patricia K.…

Team LIS

UNDERSTANDING More about DISABILITY Progression in MS – Virtual

Please register for this event by clicking the orange “Register for Virtual Event” button, below Topic Discussions: Focuses on disability progression…

Team LIS

Understanding More about Disability Progression in MS – Virtual

Please register for this event by clicking the orange “Register for Virtual Event” button, below Topic Discussions: Focused on disability progression…

Team LIS

(Currently Closed-out – No space remains) 2025 – 17th Annual MS SYMPOSIUM – South Florida

TO RSVP, PLEASE Click the: Orange RSVP ‘Going’ button, showing below. ————————————– MS Views and News Invites You to: 2025 MS SYMPOSIUM –…

Team LIS

Understanding Disability Progression in MS – Virtual

Please register for this event by clicking the orange “Register for Virtual Event” button, below Topic Discussions: * This program begins…

Team LIS

Understanding More about Disability Progression in MS – in Oak Brook, IL

TO RSVP, for this “In-Person” program,   PLEASE Click the: Orange RSVP ‘Going’ button, shown below: Click HERE to View Flyer Topic Discussions: •…

Team LIS

Categories

Latest Blog Posts